NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis

Abroad (travel likely)RecruitingPHASE1

Conditions

Refractory Systemic Lupus Erythematosus · Refractory Lupus Nephritis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Guangdong Provincial People's Hospital, Guangzhou, Guangdomg, China
Contact: Study coordinator (Xueqing Yu) · yuxueqing@gdph.org.cn

Study leads

Xueqing Yu
Principal Investigator
Guangdong Provincial People's Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis

Systemic Lupus Erythematosus · Lupus Nephritis

Abroad (travel likely)RecruitingPHASE1

Nanjing, China

CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus

Refractory Systemic Lupus Erythematosus

Abroad (travel likely)RecruitingPHASE1

Hanoi, Vietnam

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus Erythematosus · Lupus Nephritis (LN) · Sjogren's Syndrome

Abroad (travel likely)RecruitingPHASE1

Bengbu, China

Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE

Systemic Lupus Erythematosus

Abroad (travel likely)RecruitingPHASE1

Nanjing, China